Kazia Therapeutics Updates on Clinical Trial Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: PRnewswire
- Significant Clinical Responses: In the ongoing Phase 1b trial, three patients with late-stage metastatic triple-negative breast cancer treated with paxalisib demonstrated meaningful clinical responses, including two partial responses and one confirmed complete metabolic response, indicating the potential efficacy of this therapy.
- Trial Design and Patient Selection: This multi-center, open-label randomized study, initiated in June 2025, aims to evaluate the safety and preliminary efficacy of paxalisib in combination with standard treatment regimens, with eligibility requiring PD-L1 positive disease, ensuring scientific rigor and clinical relevance.
- Adverse Event Monitoring: Approximately 75% of adverse events reported during treatment were assessed as unrelated to paxalisib, with most being mild to moderate, demonstrating the drug's good tolerability and laying a foundation for future clinical applications.
- Future Development Plans: Kazia plans to activate two additional clinical trial sites by April 2026 and anticipates enrolling 12 patients by the end of 2026, further advancing paxalisib's application in broader breast cancer populations, showcasing the company's long-term commitment to this field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KZIA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KZIA
Wall Street analysts forecast KZIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZIA is 19.00 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.100
Low
18.00
Averages
19.00
High
20.00
Current: 6.100
Low
18.00
Averages
19.00
High
20.00
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kazia's NDL2 Therapy Significantly Reduces Tumor Volume
- Significant Tumor Volume Reduction: In murine triple-negative breast cancer preclinical models, NDL2 as a monotherapy reduced primary tumor volume by 49%, demonstrating its efficacy and potential as a standalone treatment option for future therapies.
- Combined Therapy Effectiveness: When combined with anti-PD-1 therapy, NDL2 reduced primary tumor volume by 73%, indicating that this combination therapy has significant potential to enhance anti-tumor activity and improve patient outcomes.
- Positive Results in Lung Metastasis Patients: In patients with lung metastases, the combination of NDL2 and anti-PD-1 therapy resulted in a 50% reduction in primary tumor volume, providing new hope for treating metastatic cancer and potentially altering clinical treatment strategies.
- Positive Market Reaction: Kazia Therapeutics' shares rose over 6% in pre-market trading on Friday, reflecting investor optimism regarding the new data on NDL2 and indicating strong market confidence in the company's future prospects.
Continue Reading
Kazia Launches First-in-Class Nuclear PD-L1 Degrader NDL2
- Novel Therapeutic Target: Kazia Therapeutics announces NDL2 as the first nuclear PD-L1 degrader, targeting a previously unaddressed mechanism of immunotherapy resistance, potentially transforming cancer treatment paradigms.
- Significant Efficacy Data: In murine triple-negative breast cancer models, NDL2 reduced primary tumor volume by 49% as monotherapy and 73% in combination with anti-PD-1, demonstrating its robust anti-tumor activity.
- Safety and Pharmacokinetics: NDL2 showed no toxicity in preclinical trials, preserving immune checkpoint function at the cell surface, indicating its potential safety and efficacy in clinical applications.
- Future Development Outlook: Kazia plans to initiate first-in-human clinical trials in 2027 targeting immunotherapy-refractory solid tumors, with NDL2's development expected to create strategic partnership opportunities and long-term value.
Continue Reading